Efficacy and safety of European Medicines Agency ( <scp>EMA</scp> )‐approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta‐analysis of randomised controlled trials for the development of the <scp
In patients affected by mild to moderate obesity, newer OMMs (i.e., tirzepatide and semaglutide) appear to be valid alternatives to EBP and MBS. They could be preliminarily chosen as a first-line option based on similar efficacy and greater safety and tolerability. Higher degrees of obesity could be more effectively treated with MBS, the efficacy of which, with the notable exception of LAGB and GCP, appears superior to other treatments, especially in the long term.
Authors
- Giovanni Antonio Silverii (ORCID: https://orcid.org/0000-0002-6695-3213)
- Benedetta Ragghianti
- Amanda Belluzzi
- Paolo Sbraccia (ORCID: https://orcid.org/0000-0001-9634-1501)
- Gian Maria Busetto (ORCID: https://orcid.org/0000-0002-7291-0316)
- Silvio Buscemi (ORCID: https://orcid.org/0000-0003-0730-7649)
- Giuseppe Navarra (ORCID: https://orcid.org/0000-0003-0372-1615)
- Matteo Monami (ORCID: https://orcid.org/0000-0001-9349-828X)
- Edoardo Mannucci (ORCID: https://orcid.org/0000-0001-9759-9408)
- Maurizio De Luca (ORCID: https://orcid.org/0000-0001-7642-0915)
- Rocco Barazzoni (ORCID: https://orcid.org/0000-0002-4049-2404)
Institutions
- University of Messina (IT)
- University of Rome Tor Vergata (IT)
- University of Padua (IT)
- University of Trieste (IT)
- Italian Society of Physiotherapy (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Ospedale Santa Maria della Misericordia di Rovigo (IT)
- University of Palermo (IT)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-10-20
- DOI
- https://doi.org/10.1111/dom.70204
- Citations
- 1
- Primary Topic
- Bariatric Surgery and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.01